Low-dose aripiprazole: Stanford chart review
Crosby LD et al. · 2021 · Journal of Translational Medicine
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Retrospective review. Reported daily doses ranged from 0.2 to 2.0 mg, with a mean dose of about 1.1 mg.
Dose, route and schedule
Retrospective review. Reported daily doses ranged from 0.2 to 2.0 mg, with a mean dose of about 1.1 mg.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported improvement | 75/101 (74.3%) improved in at least one symptom domain. | |
| No improvement or worsening | 12/101 (11.9%) reported no change and 14/101 (13.9%) worsened or discontinued because of adverse effects. |
There was no placebo group, and the response was based on clinical reports rather than a prespecified randomized outcome.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- There was no placebo group, and the response was based on clinical reports rather than a prespecified randomized outcome.
Source access
Retrospective review. Reported daily doses ranged from 0.2 to 2.0 mg, with a mean dose of about 1.1 mg.
Source reviewed 2026-11-12.
Citation and original source
Original source: Crosby LD et al.. Low-dose aripiprazole: Stanford chart review Journal of Translational Medicine 2021.
Molekul research summary: https://molekul.io/research/aripiprazole-crosby-2021. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry